KRISTIN HANCOCK: Open Payments
NPI 1740809706 · SPRING BRANCH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$764 in 33 payments from 13 companies in 2025. Trend: 2023 $615 · 2024 $819 · 2025 $764
Food & beverage: $764
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $208 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $109 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $95 |
| Aimmune Therapeutics, Inc. | 3 | $59 |
| Madrigal Pharmaceuticals | 3 | $55 |
| Ipsen Biopharmaceuticals, Inc | 3 | $50 |
| GENZYME CORPORATION | 2 | $47 |
| Celltrion USA Inc. | 2 | $41 |
| Ardelyx, Inc. | 1 | $24 |
| VIVUS LLC | 1 | $21 |
Products named: XIFAXAN, VOWST, REZDIFFRA, IQIRVO, ENTYVIO, DUPIXENT, EOHILIA, VEGZELMA.
Industry payments across TX — which companies pay providers there.
